ConductScience.org, home

Paper28291388

Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels.

Kochenderfer JN and 21 others. J Clin Oncol, 2017. Cited by 487 papers, by iCite.

Cite this record

ConductScience Library. Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels. Papers, record 28291388. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28291388

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels.
PubMed
Journal
J Clin Oncol
PubMed
Year
2017
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
487
iCite
Relative citation ratio, by iCite
14.2
iCite
Revised in PubMed
2021-01-03
PubMed

Authors22

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Kochenderfer JNJames N
2Somerville RPTRobert P T
3Lu TTangying
4Shi VVictoria
5Bot AAdrian
6Rossi JJohn
7Xue AAllen
8Goff SLStephanie L
9Yang JCJames C
10Sherry RMRichard M
11Klebanoff CAChristopher A
12Kammula USUdai S
13Sherman MMarika
14Perez AArianne
15Yuan CMConstance M
16Feldman TTatyana
17Friedberg JWJonathan W
18Roschewski MJMark J
19Feldman SASteven A
20McIntyre LLori

Source PubMed

See all 22 authorsDownload CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Immunotherapy, AdoptiveMajor topic
Interleukin-15Major topic
LymphomaMajor topic
T-LymphocytesMajor topic
Adult
Aged
Antigens, CD19
Cyclophosphamide
Humans
Middle Aged
Receptors, Antigen, T-Cell
Transplantation Conditioning
Vidarabine

Source PubMed

Download CSV of topics

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
ZIABC011417NIHNIH RePORTER
ZICBC011569NIHNIH RePORTER

Download CSV of grants

Trials2

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT00924326CAR T Cell Receptor Immunotherapy for Patients With B-cell LymphomaResultsClinicalTrials.gov
NCT06339255Italian Observational Study on CAR-T Therapy for LymphomaResultsClinicalTrials.gov

Download CSV of trials

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in28352132Immunotherapy: DLBCL remissions driven by CARs.https://conductscience.org/library/papers/28352132

Source PubMed

Download CSV of comments and corrections

References52

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
122952817Granzyme B-induced neurotoxicity is mediated via activation of PAR-1 receptor and Kv1.3 channel.PLoS One2012https://conductscience.org/library/papers/22952817PubMed
226325036CAR therapy: the CD19 paradigm.J Clin Invest2015https://conductscience.org/library/papers/26325036PubMed
320668228Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.Blood2010https://conductscience.org/library/papers/20668228PubMed
416203864Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells.J Exp Med2005https://conductscience.org/library/papers/16203864PubMed
527605551Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells.Sci Transl Med2016https://conductscience.org/library/papers/27605551PubMed
620428207Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety.Leukemia2010https://conductscience.org/library/papers/20428207PubMed
727482888Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells.J Clin Invest2016https://conductscience.org/library/papers/27482888PubMed
823344265B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.Clin Cancer Res2013https://conductscience.org/library/papers/23344265PubMed
917242396Revised response criteria for malignant lymphoma.J Clin Oncol2007https://conductscience.org/library/papers/17242396PubMed
1025317870Chimeric antigen receptor T cells for sustained remissions in leukemia.N Engl J Med2014https://conductscience.org/library/papers/25317870PubMed
1124778315IL-10: master switch from tumor-promoting inflammation to antitumor immunity.Cancer Immunol Res2014https://conductscience.org/library/papers/24778315PubMed
1224553386Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.Sci Transl Med2014https://conductscience.org/library/papers/24553386PubMed
1319561539Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor.J Immunother2009https://conductscience.org/library/papers/19561539PubMed
1426811520
Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease.
J Clin Oncol2016https://conductscience.org/library/papers/26811520PubMed
1523375551Diffuse large B-cell lymphoma.Crit Rev Oncol Hematol2013https://conductscience.org/library/papers/23375551PubMed
166460831Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells.J Exp Med1982https://conductscience.org/library/papers/6460831PubMed
1722581824IL-10 directly activates and expands tumor-resident CD8(+) T cells without de novo infiltration from secondary lymphoid organs.Cancer Res2012https://conductscience.org/library/papers/22581824PubMed
1826627006IL15 and T-cell Stemness in T-cell-Based Cancer Immunotherapy.Cancer Res2015https://conductscience.org/library/papers/26627006PubMed
1911568001Interleukin-10 promotes the maintenance of antitumor CD8(+) T-cell effector function in situ.Blood2001https://conductscience.org/library/papers/11568001PubMed
2020631379Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells.Blood2010https://conductscience.org/library/papers/20631379PubMed

See all 52 referencesDownload CSV of references

Cited by368

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 487 citations.

PMIDTitleJournalYearIn PapersSource
42969556Bendamustine induces peripheral lymphodepletion in dogs with relapsed lymphoma.J Vet Intern Med2026https://conductscience.org/library/papers/42969556PubMed
42816506Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.Signal Transduct Target Ther2026https://conductscience.org/library/papers/42816506PubMed
42605790Metabolic activation using fructose-1,6-bisphosphate microparticles of non-virally LNP-generated CAR-macrophages induces anti-tumor immune responses.J Mater Chem B2026https://conductscience.org/library/papers/42605790PubMed
42187436Machine Learning-Assisted Rapid Optical Imaging for Label-Free CAR T-Cell Detection in Whole Blood.Biosensors (Basel)2026https://conductscience.org/library/papers/42187436PubMed
42066750Distinct in vivo dynamics of donor-derived stem cell memory CAR T cells post-allogeneic HSCT relapse.Cell2026https://conductscience.org/library/papers/42066750PubMed
41998030Hematological parameters as predictive indicators of disease stage in patients with cervical cancer.Sci Rep2026https://conductscience.org/library/papers/41998030PubMed
41912833Baseline absolute lymphocyte count, C-reactive protein, and ferritin predict CAR T cell-related toxicities and outcomes in multiple myeloma.Bone Marrow Transplant2026https://conductscience.org/library/papers/41912833PubMed
418310876-month Progression-Free Survival (PFS6) as a prognostic factor in large B-cell lymphoma patients undergoing chimeric antigen receptor T-cell therapy: A real-world multicenter study.Ann Hematol2026https://conductscience.org/library/papers/41831087PubMed
41702648Corticosteroids ameliorate CAR T-cell-induced cytokine-release syndrome without inhibiting multiple myeloma treatment.J Immunother Cancer2026https://conductscience.org/library/papers/41702648PubMed
41686452Ibrutinib exposure correlates with improved efficacy of CAR T cells in patients with mantle cell lymphoma.Blood Adv2026https://conductscience.org/library/papers/41686452PubMed
41591467Unleashing CAR-T potential in solid tumors: overcoming intrinsic and extrinsic hurdles to improve therapy.Cancer Immunol Immunother2026https://conductscience.org/library/papers/41591467PubMed
41559435CAR-engineered cell therapies: current understandings and future perspectives.Mol Biomed2026https://conductscience.org/library/papers/41559435PubMed
41516067Pre-Treatment with Dacarbazine Sensitizes B16 Melanoma to CAR T Cell Therapy in Syngeneic Mouse Model.Int J Mol Sci2025https://conductscience.org/library/papers/41516067PubMed
41507382Can modified lymphodepletion before tisagenlecleucel improve outcome in high-risk patients with large B-cell lymphoma?Bone Marrow Transplant2026https://conductscience.org/library/papers/41507382PubMed
41492094Axicabtagene ciloleucel in combination with rituximab for refractory large B cell lymphoma: the phase 2, single-arm ZUMA-14 trial.Nat Cancer2026https://conductscience.org/library/papers/41492094PubMed
41324276The Pleiotropic Roles of Cytokines in Chimeric Antigen Receptor T-cell Therapy.Cancer Immunol Res2026https://conductscience.org/library/papers/41324276PubMed
41306534Case Report: Rare adverse events following CAR-T therapy in patients with relapsed/refractory diffuse large B-cell lymphoma.Front Oncol2025https://conductscience.org/library/papers/41306534PubMed
41024300Transforming cancer immunotherapy: integration of distinct immune-based approaches as redefined dual immunotherapy with potential third-sensitizer.Exp Hematol Oncol2025https://conductscience.org/library/papers/41024300PubMed
40873568CAR T-cell therapy in autoimmune diseases: a promising frontier on the horizon.Front Immunol2025https://conductscience.org/library/papers/40873568PubMed
40847431Revolutionizing cardiac fibrosis treatment: the potential of personalized CAR T-cell therapy.Cardiooncology2025https://conductscience.org/library/papers/40847431PubMed

See all 368 cited byDownload CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD19930PubTator's text mininghttps://conductscience.org/library/genes/930NCBI Gene
CXADRP1653108PubTator's text mininghttps://conductscience.org/library/genes/653108NCBI Gene
IL153600PubTator's text mininghttps://conductscience.org/library/genes/3600NCBI Gene

Download CSV of genes

Drugs3

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
CYCLOPHOSPHAMIDECHEMBL1200796Results1https://conductscience.org/library/drugs/CHEMBL1200796ChEMBL
ALDESLEUKINCHEMBL1201438Results1https://conductscience.org/library/drugs/CHEMBL1201438ChEMBL
FLUDARABINECHEMBL1568Results1https://conductscience.org/library/drugs/CHEMBL1568ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/28291388

GET https://conductscience.org/api/papers/v1/28291388/authors?page=2